Download Files:
Products Details
Product Description
– Piroxicam-d4 is the deuterium labeled Piroxicam. Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.
Web ID
– HY-B0253S1
Shipping
– Room temperature
Molecular Formula
– C15H9D4N3O4S
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Kato M, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001 Dec;53(12):1679-85.|[3]Mohammed SI, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002 Jan 15;62(2):356-8.|[4]Silva J, et al. Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. Anticancer Res. 2017 Apr;37(4):1737-1745.
Molecular Weight
– 335.37
SMILES
– O=C(C1=C(O)C2=CC=CC=C2S(N1C)(=O)=O)NC3=NC([2H])=C([2H])C([2H])=C3[2H]
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Cancer
Solubility
– 10 mM in DMSO
Target
– COX;Isotope-Labeled Compounds
Pathway
– Immunology/Inflammation;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
